The National Comprehensive Cancer Network (NCCN) has appointed Robert C. Young, MD, as Interim Vice President of the NCCN Oncology Research Program.
Dr. Young brings to NCCN more than 45 years of oncology experience. He is President of RCY Medicine, a consulting service focused on cancer center productivity, health-care quality, and health policy, and served as President and CEO of Fox Chase Cancer Center for 18 years, following which he served 2 years as Chancellor. Dr. Young is internationally known for his expertise in the treatment of lymphoma and ovarian cancer.
As Interim Vice President, Dr. Young will be responsible for developing and managing NCCN’s centralized, standardized infrastructure for the conduct of clinical trials among its 26 NCCN member institutions and their community affiliates. The Oncology Research Program fosters collaboration among NCCN Member Institutions and pharmaceutical and biotechnology companies to bring promising and effective new treatments to patients with cancer and publishes important resources for clinical investigators.
Dr. Young has served as President of ASCO, The American Cancer Society, and the International Gynecological Cancer Society, respectively, as well as Chairman of the NCCN Board of Directors and Chair of the National Cancer Institute (NCI) Board of Scientific Advisors. He also served as a member of the National Cancer Policy Board of the Institute of Medicine.
Since 2010, Dr. Young has been a member of the NCCN Foundation Board of Directors, and he currently serves on the Board of Directors of AVEO Pharmaceuticals, Inc. ■